PerkinElmer Receives FDA Clearance to Market Breakthrough Newborn Screening System; Novel Detection System Screens for Metabolic Deficiency.

Business/Technology Editors and Health/Medical Writers

BOSTON--(BW HealthWire)--Nov. 13, 2002

PerkinElmer, Inc. (NYSE: PKI), the leading provider of solutions to newborn screening laboratories, today announced it is the first company to receive FDA 510(k) certification to market a comprehensive screening system to identify whether a newborn may become developmentally impaired or risk premature death. PerkinElmer's NeoGram(TM) Phenylalanine Test System, consisting of a reagent kit, application software and tandem mass spectrometer, will be used worldwide in the identification of a disorder known as phenylketonuria (PKU), in newborns.

PKU is an inborn error of metabolism characterized by the lack of the phenylalanine dehydrogenase enzyme. Without this enzyme, the body is unable to break down the amino acid, phenylalanine, commonly found in food proteins. As a result, phenylalanine builds up in the bloodstream causing several maladies, including irreversible mental retardation and premature death. Early detection of the disorder in newborns allows the administration of a phenylalanine-restricted diet to ensure that the infant will develop normally. Approximately one newborn in every 10,000 is PKU positive. This disorder occurs in all ethnic groups, although it is most common in individuals of Northern European ancestry.

PerkinElmer's NeoGram Phenylalanine Test System includes a reagent kit with standards, controls and reagents manufactured under Good Manufacturing Practices (GMP) and FDA guidelines to produce accurate and consistent results. The reagent kit is designed to run exclusively on tandem mass spectrometry equipment, recognized as the latest technological advancement for newborn screening. Bringing the system together is the NeoGram application-specific software, which was developed exclusively by PerkinElmer's software engineers.

"Tandem Mass Spectrometry (MS/MS) is a highly sensitive and specific detection methodology that has significant potential in newborn screening," said Harry Hannon, Ph.D., director of Neonatal Quality Assurance, Center for Disease Control in Atlanta, Georgia.

Identification of likely PKU cases by the NeoGram Phenylalanine Test System is accomplished by isotope dilution MS/MS, whereby a sample extracted with a solution containing relevant internal standards from the kit is introduced into the tandem mass spectrometer (two mass filters linked by a central collision cell). The first mass filter selects Phenylalanine and Tyrosine (a byproduct of the phenylalanine metabolic pathway), and the corresponding internal standards out of the complex sample matrix. The selected compounds are then directed to the central collision cell where each of them is broken down into smaller fragments. The second mass filter selects fragments that are highly specific for each of these amino acids, and the intensities are recorded by the detection system. The relative intensities are used to calculate the concentrations of the analytes, subsequently used to determine the likelihood that a newborn tests positive for PKU.

"Receipt of the 510(k) certification allows us to commercially market our phenylalanine test kit utilizing tandem mass spectrometry, which will help to improve and save the lives of newborns around the world," said Peter Coggins, Ph.D., president, PerkinElmer Life and Analytical Sciences. "It is a significant milestone in newborn screening and exemplifies our commitment to use our industry-leading screening technologies to improve the lives of individuals from birth through adulthood. It is our goal to provide industry standard screening solutions that will yield comparable results no matter where in the world tests are performed."

PerkinElmer is the market leader as a complete solutions provider to newborn screening laboratories. Currently 18 million newborns a year in 46 countries are screened using PerkinElmer technologies.

For more information on PerkinElmer's neonatal screening products, please visit http://lifesciences.perkinelmer.com/producttemplates/Category. asp?levelId=16140.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including the possibility that our proposed new financing with Merrill Lynch is not consummated, including without limitation as a result of an inability to satisfy the conditions to Merrill Lynch's obligations set forth in the commitment agreement, risks related to our debt levels, a downturn in our customers' markets, our failure to introduce new products in a timely manner, risks related to our international operations, our inability to integrate acquired businesses into our existing business, competition and other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recently filed quarterly report on Form 10-Q. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life Sciences, Optoelectronics, Analytical Instruments, and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer creates innovative solutions - backed by unparalleled service and support - for customers in health sciences, semiconductor, aerospace, and other markets whose applications demand absolute precision and speed. The company operates in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.